Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04519879 · ClinicalTrials.gov registry record · Phase 2
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
A Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 133
- Enrollment target
- 7
- Study locations
NCT04519879: Active Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, sponsored by City of Hope Medical Center.
NCT04519879 is a Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 133 participants, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (39% lower). The trial reports 7 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04519879, a Phase 2 study of Prostate Adenocarcinoma and Recurrent Prostate Carcinoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 133 participants
- Enrollment target
- 7
- Study locations
Study Summary
This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not undergone any therapy (therapy naive). PSA is a blood marker of prostate growth. White button mushroom supplement may affect PSA level, various parameters of immune system and levels of hormones that may have a role in prostate cancer growth.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Clinical Observation
- OTHER Patient Observation
- DRUG White Button Mushroom Extract
Study Locations (7)
California
- City of Hope Medical Center - Duarte
- City of Hope at Glendora - Glendora
- City of Hope at Irvine Lennar - Irvine
- City of Hope Rancho Cucamonga - Rancho Cucamonga
- John Wayne Cancer Institute - Santa Monica
- City of Hope South Pasadena - South Pasadena
- City of Hope West Covina - West Covina
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 133 participants |
| Start Date | 2021-05-10 |
| Est. Completion | 2026-05-14 |
| Phase | Phase 2 |
What the registry record for NCT04519879 still lists
NCT04519879 is an interventional study that assigns participants to a tested intervention. The registered 133 participants enrollment target is mid-sized for trials with a published cap, below the 217-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (39% lower).
The record links to 10 conditions, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT04519879 lists 7 locations in 1 state (California).
Frequently Asked Questions
What is clinical trial NCT04519879 about?
NCT04519879 is a clinical study titled "White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA". This phase II trial studies how well white button mushroom supplement works in reducing prostate-specific antigen (PSA) levels in patients with prostate cancer that has come back (recurrent) or has favorable risk and has not undergone any therapy (therapy naive). PSA is a blood marker of prostate gr...
What is the current status of trial NCT04519879?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 133 participants. The study started on 2021-05-10. Estimated completion is 2026-05-14.
What conditions does trial NCT04519879 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT04519879?
The interventions under investigation include: Questionnaire Administration (OTHER), Clinical Observation (OTHER), Patient Observation (OTHER), White Button Mushroom Extract (DRUG).
Who is sponsoring clinical trial NCT04519879?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04519879 being conducted?
This trial has 7 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04519879's enrollment target sits among peer trials
133 30th of 99 higher than 70 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
RECRUITING · Phase 2
-
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
RECRUITING · Phase 2
-
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
RECRUITING · Phase 2
-
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276870 · 133 participants · Phase 2
Orphan Indications for CD19 Redirected Autologous T Cells
- NCT04671771 · 133 participants · NA
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
- NCT05610085 · 133 participants · Phase 2
A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures
- NCT06206486 · 133 participants
The Gut Microbiome and Serum Metabolites As a Biological Mechanism Underlying Pain in Kidney Transplantation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI